Drug Profile


Alternative Names: BPI 2358; NPI 2358

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer BeyondSpring Pharmaceuticals; National Cancer Institute (USA); Nereus Pharmaceuticals; University of Washington
  • Class Antineoplastics; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II/III Neutropenia
  • Phase I Solid tumours
  • Preclinical Glioblastoma
  • Research Brain cancer

Most Recent Events

  • 28 Apr 2017 BeyondSpring plans a phase II/III trial for Neutropaenia (Combination therapy)
  • 28 Apr 2017 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in Australia (IV)
  • 28 Apr 2017 BeyondSpring intends to file an IND application for phase III trial in Neutropenia (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top